The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
Overview
Authors
Affiliations
Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26-156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy's and Knosp's grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp's grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp's grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET.
Bai X, Duan L, Yang S, Wang T, Yao Y, Zhang M Front Endocrinol (Lausanne). 2025; 16:1526625.
PMID: 40065992 PMC: 11891042. DOI: 10.3389/fendo.2025.1526625.
Predictors of growth hormone level on postoperative day one in patients with acromegaly.
Li H, Li Z, Feng T, Chen Y, Zhong J, Wei L Endocrine. 2024; .
PMID: 39707075 DOI: 10.1007/s12020-024-04130-6.
Grading and staging for pituitary neuroendocrine tumors.
Villa C, Birtolo M, Perez-Rivas L, Righi A, Assie G, Baussart B Brain Pathol. 2024; 35(1):e13299.
PMID: 39182993 PMC: 11669418. DOI: 10.1111/bpa.13299.
Pronin V, Antsiferov M, Alekseeva T, Pronin E, Lapshina A, Urusova L Probl Endokrinol (Mosk). 2024; 70(3):31-45.
PMID: 39069771 PMC: 11334236. DOI: 10.14341/probl13376.
Pituitary Tumors: Molecular Insights, Diagnosis, and Targeted Therapy.
Kageyama K, Nishiyama M Cancers (Basel). 2023; 15(23).
PMID: 38067229 PMC: 10705121. DOI: 10.3390/cancers15235526.